---
title: "TOT BIOPHARM Receives Voluntary Cash Offer at 99% Premium"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/272578717.md"
description: "TOT BIOPHARM International Co. Ltd. (HK:1875) has received a voluntary cash offer from Citigroup Global Markets Asia Limited to acquire all issued shares not already owned by the offeror at HK$4.00 per share, representing a 99% premium over the last trading price. This offer indicates a potential change of control and is significant for Wuxi Biologics. Trading in TOT BIOPHARM shares will resume as the market assesses the implications for minority shareholders. The current analyst rating for the stock is a Hold with a price target of HK$2.50."
datetime: "2026-01-14T15:10:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/272578717.md)
  - [en](https://longbridge.com/en/news/272578717.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/272578717.md)
---

# TOT BIOPHARM Receives Voluntary Cash Offer at 99% Premium

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

The latest update is out from TOT BIOPHARM International Co. Ltd. ( (HK:1875) ).

Citigroup Global Markets Asia Limited will, on behalf of an offeror, launch voluntary conditional cash offers to acquire all issued shares of TOT BIOPHARM International Co. Ltd. not already owned by the offeror and its concert parties at HK$4.00 per share and to cancel all outstanding share options. The offer price represents a roughly 99% premium to the company’s last undisturbed trading price and will not be increased, signalling a potentially significant change of control that could constitute a major transaction for the offeror and a discloseable transaction for Wuxi Biologics, while trading in the company’s shares is set to resume as the market digests the proposed deal and its implications for minority shareholders and the company’s future ownership structure.

The most recent analyst rating on (HK:1875) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

**More about TOT BIOPHARM International Co. Ltd.**

TOT BIOPHARM International Co. Ltd. is a biopharmaceutical company listed in Hong Kong that develops, manufactures and commercialises oncology and other biologic drugs, with its shares traded under stock code 1875 and operating alongside related entities incorporated in the Cayman Islands and Hong Kong. The group is positioned within the broader biologics and oncology therapeutics market, serving investors seeking exposure to innovative pharmaceutical and biotech assets in Greater China.

**Average Trading Volume:** 195,463

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$1.93B

For an in-depth examination of 1875 stock, go to TipRanks’ Overview page.

### Related Stocks

- [01875.HK](https://longbridge.com/en/quote/01875.HK.md)

## Related News & Research

- [A Look At Zai Lab (ZLAB) Valuation After Recent Share Price Weakness](https://longbridge.com/en/news/288310385.md)
- [Rising Stars: WPP’s Meghan O’Hora](https://longbridge.com/en/news/288530239.md)
- [Elon Musk's SpaceX Just Made An IPO Filing Change That Has Tesla Investors Buzzing](https://longbridge.com/en/news/288382396.md)
- [Wockhardt soars 19%, zooms 75% in 1 month; what's driving pharma stock?](https://longbridge.com/en/news/288213295.md)
- [Pak Fah Yeow Wins Strong Shareholder Backing for Dividends, Mandates and Bye-law Changes](https://longbridge.com/en/news/288400033.md)